TQ05105 (JAK2 inhibitor)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-02 — A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis: Early-phase clinical trial announced evaluating TQ05105 tablets in moderate- and high-risk myelofibrosis; no efficacy or safety data yet reported. (novelty: 3)
Open questions
Related
Contributing findings
A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
03-jun-2026
novelty 2
per-area 2
strengthens
A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis
02-jun-2026
novelty 3
per-area 3
introduces